Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23526210 | 1.00 | MEN1 (0.44) | MEN1KMT2AACHECES2LMNA | |
| SCHEMBL23526213 | 1.00 | MEN1 (0.44) | MEN1KMT2AACHECES2LMNA | |
| SCHEMBL23526211 | 1.00 | MEN1 (0.44) | MEN1KMT2AACHECES2LMNA | |
| SCHEMBL20792450 | 0.85 | KMT2A (0.52) | MEN1KMT2ACES2LMNAPOLB | |
| SCHEMBL21132427 | 0.85 | KMT2A (0.52) | MEN1KMT2ACES2LMNAPOLB | |
| SCHEMBL21133185 | 0.85 | KMT2A (0.43) | MEN1KMT2AACHECES2LMNA | |
| SCHEMBL21133184 | 0.85 | KMT2A (0.43) | MEN1KMT2AACHECES2LMNA | |
| SCHEMBL29755156 | 0.85 | KMT2A (0.43) | MEN1KMT2AACHECES2LMNA | |
| SCHEMBL22321401 | 0.85 | KMT2A (0.52) | MEN1KMT2ACES2LMNAPOLB | |
| SCHEMBL29949168 | 0.85 | KMT2A (0.52) | MEN1KMT2ACES2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419962-B2 | Quinazolines, pharmaceutical compositions, and therapeutic applications | BIOTHERYX, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419962-B2 | Quinazolines, pharmaceutical compositions, and therapeutic applications | RAB1A, SOS1, IQGAP1 | MEN1 236/4885KMT2A 4124/4885ACHE 1340/4885 |
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | RAB1A, SOS1, IQGAP1 | MEN1 236/4885KMT2A 4124/4885ACHE 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.